Related Experiment Video
Updated: Jul 13, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[CD5- CD11c+ CD23- small lymphocytic lymphoma evolving from aplastic anemia]
Motoo Kikuchi1, Toshiaki Inagaki, Ryuzo Ueda
1Department of Medicine, Nagoya-Shi Kouseiin Medical Welfare Center.
Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
|September 25, 2004
Summary
Aplastic anemia evolved into a rare small lymphocytic lymphoma in an elderly patient. Treatment with rituximab showed some improvement, highlighting a unique case of lymphoma with specific cell markers.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- A 91-year-old woman initially diagnosed with aplastic anemia (AA) in 1997.
- AA was characterized by pancytopenia and hypocellular bone marrow without myeloblasts or dysplasia.
Observation:
- The patient presented with persistent fever and leukopenia in 2001.
- Bone marrow examination revealed small lymphocytic proliferation with a unique immunophenotype (CD5- CD10- CD11c+ CD19+ CD20+ CD23-).
- Genetic analysis showed immunoglobulin heavy chain rearrangement and abnormal chromosomes.
Findings:
- A diagnosis of small lymphocytic lymphoma (SLL) evolving from AA was made.
- Treatment with rituximab resulted in decreased lactate dehydrogenase and soluble interleukin-2 receptor levels.
- Partial improvement in platelet and erythrocyte counts and overall systemic condition was observed.
Implications:
- This case highlights a rare SLL subtype with a distinct CD marker profile.
- The evolution of AA to SLL presents a unique clinical scenario.
- Rituximab demonstrated potential efficacy in managing this rare lymphoma subtype, despite incomplete remission.
